GuidelineCurrent

ECMM/MSG ERC 2019 — Global guideline for the diagnosis and management of mucormycosis

European Confederation of Medical Mycology / Mycoses Study Group Education and Research Consortium, 2019

Treat suspected or proven mucormycosis urgently with multidisciplinary source control when feasible and an active systemic antifungal. High-dose liposomal amphotericin B is strongly recommended first-line; isavuconazole or delayed-release/IV posaconazole are alternatives in selected settings and important salvage options.

Strong recommendationModerate certainty

View source guideline

Clinical Context & Relevant Topics (1)

Disease Reference

Candidemia & Invasive Candidiasis

ICU recognition and treatment of candidemia and invasive candidiasis, including source control, repeat cultures, step-down therapy and metastatic infection.

View Topic Context →